Real-world evidence in achondroplasia: considerations for a standardized data setDepartment of Medical Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Department of Internal Medicine, Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands.
Hôpital Necker Enfants Malades AP-HP, Paris, France.
Genetic and Genomic Medicine Division, Sidra Medicine and Hamad Medical Corporation, Doha, Qatar.
Department of Paediatrics, UKE Hamburg-Eppendorf, Hamburg, Germany.
Hôpital Necker Enfants Malades AP-HP, Paris, France; Reference Center for Skeletal Dysplasia, Imagine Institute, Paris Cité University, Paris, France.
Department of Clinical Genetics and Centre for Rare Diseases, Aarhus University Hospital, Aarhus, Denmark.
Medical Genetics Section, Department of Paediatrics, Virgen de la Arrixaca University Clinical Hospital, IMIB-Arrixaca, Faculty of Medicine, University of Murcia (UMU), Murcia, Spain.
Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.
Department of Paediatrics, IRCCS Istituto Giannna Gaslini, Genoa, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology Genetics, Maternal and Child-Health, University of Genova, Genoa, Italy.
BioMarin (UK) Limited, London, UK.
BioMarin (UK) Limited, London, UK.
BioMarin (UK) Limited, London, UK.
Pediatric Unit ASST Lariana, Mariani Center for Fragile Child, Como, Italy.
Faculty of Medicine, University of Cologne, Cologne, Germany; Department of Pediatrics, University Hospital Cologne, Cologne, Germany.
Département de Génétique Médicale, Hôpital Timone Enfant, Marseille, France.
National Ilizarov Research Center for Traumatology and Orthopaedics, Kurgan, Russia.
BioMarin (UK) Limited, London, UK.
Fundación ALPE Acondroplasia, Asturias, Spain.
Associazione per I'Informazione e lo Studio dell'Acondroplasia (AISAC), Milan, Italy.
Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK.
Show others and affiliations
2023 (English)In: Orphanet Journal of Rare Diseases, E-ISSN 1750-1172, Vol. 18, no 1, article id 166Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Collection of real-world evidence (RWE) is important in achondroplasia. Development of a prospective, shared, international resource that follows the principles of findability, accessibility, interoperability, and reuse of digital assets, and that captures long-term, high-quality data, would improve understanding of the natural history of achondroplasia, quality of life, and related outcomes.
METHODS: The Europe, Middle East, and Africa (EMEA) Achondroplasia Steering Committee comprises a multidisciplinary team of 17 clinical experts and 3 advocacy organization representatives. The committee undertook an exercise to identify essential data elements for a standardized prospective registry to study the natural history of achondroplasia and related outcomes.
RESULTS: A range of RWE on achondroplasia is being collected at EMEA centres. Whereas commonalities exist, the data elements, methods used to collect and store them, and frequency of collection vary. The topics considered most important for collection were auxological measures, sleep studies, quality of life, and neurological manifestations. Data considered essential for a prospective registry were grouped into six categories: demographics; diagnosis and patient measurements; medical issues; investigations and surgical events; medications; and outcomes possibly associated with achondroplasia treatments.
CONCLUSIONS: Long-term, high-quality data are needed for this rare, multifaceted condition. Establishing registries that collect predefined data elements across age spans will provide contemporaneous prospective and longitudinal information and will be useful to improve clinical decision-making and management. It should be feasible to collect a minimum dataset with the flexibility to include country-specific criteria and pool data across countries to examine clinical outcomes associated with achondroplasia and different therapeutic approaches.
Place, publisher, year, edition, pages
BioMed Central (BMC), 2023. Vol. 18, no 1, article id 166
Keywords [en]
Achondroplasia, Growth, Quality of life, Rare disease, Real-world data, Real-world evidence, Registry
National Category
Medical Genetics
Identifiers
URN: urn:nbn:se:oru:diva-106615DOI: 10.1186/s13023-023-02755-wISI: 001016781800002PubMedID: 37365619Scopus ID: 2-s2.0-85163344717OAI: oai:DiVA.org:oru-106615DiVA, id: diva2:1775895
Note
Funding agency:
Johnson & Johnson
2023-06-272023-06-272024-03-14Bibliographically approved